ECONAZOLE NITRATE CREAM, 1%

Manufacturer
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
Effective date
2019-02-22
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
7
Source
legacy-cache
Hydrated at
2026-08-02 00:30:40

Label at a glance#

ProductEconazole Nitrate
Active ingredientECONAZOLE NITRATE
Label structure13 sections

Indications and uses

Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by  Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and  Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.

Dosage and administration

Sufficient Econazole Nitrate Cream, 1% should be applied to cover affected areas once daily in patients with tinea pedis, tinea cruris, tinea corporis, and tinea versicolor, and twice daily (morning and evening) in patients with cutaneous candidiasis. Early relief of symptoms is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun; however, candidal infe...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

FOR TOPICAL USE ONLY.

DESCRIPTION:

DESCRIPTION SECTION

Econazole Nitrate Cream, 1% contains the antifungal agent, Econazole Nitrate USP 1%, in a water-miscible base consisting of pegoxyl 7 stearate, peglicol 5 oleate, mineral oil, benzoic acid, butylated hydroxyanisole, and purified water. The white to off-white soft cream is for topical use only.

Chemically, econazole nitrate is 1-[2-{(4-chloro-phenyl)methoxy}-2-(2,4 dichlorophenyl)ethyl]-1H-imidazole mononitrate. Its structure is as follows:

Structural Formula
Structural Formula

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

After topical application to the skin of normal subjects, systemic absorption of econazole nitrate is extremely low. Although most of the applied drug remains on the skin surface, drug concentrations were found in the stratum corneum which, by far, exceeded the minimum inhibitory concentration for dermatophytes. Inhibitory concentrations were achieved in the epidermis and as deep as the middle region of the dermis. Less than 1% of the applied dose was recovered in the urine and feces.

MICROBIOLOGY SECTION

Microbiology: Econazole nitrate has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

Dermatophytes

Yeasts

Epidermophyton floccosum

Candida albicans

Microsporum audouini

Malassezia  furfur

Microsporum canis

Microsporum gypseum

Trichophyton mentagrophytes

Trichophyton rubrum

Trichophyton tonsurans

Econazole nitrate exhibits broad-spectrum antifungal activity against the following organisms in vitro, but the clinical significance of these data is unknown.

Dermatophytes

Yeasts

Trichophyton verrucosum

Candida guillermondii

Candida parapsilosis

Candida  tropicalis

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Econazole Nitrate Cream, 1% is contraindicated in individuals who have shown hypersensitivity to any of its ingredients.

WARNINGS:

WARNINGS SECTION

Econazole Nitrate Cream, 1% is not for ophthalmic use.

PRECAUTIONS:

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General: If a reaction suggesting sensitivity or chemical irritation should occur, use of the medication should be discontinued.

For external use only. Avoid introduction of Econazole Nitrate Cream into the eyes.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Drug Interactions: Warfarin: Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulation effect. Most cases reported product application with use under occlusion, genital application, or application to large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.

Carcinogenesis Studies: Long-term animal studies to determine carcinogenic potential have not been performed.

SPL UNCLASSIFIED SECTION

Fertility (Reproduction): Oral administration of econazole nitrate in rats has been reported to produce prolonged gestation. Intravaginal administration in humans has not shown prolonged gestation or other adverse reproductive effects attributable to econazole nitrate therapy.

PREGNANCY SECTION

Pregnancy: Pregnancy Category C: Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats. Fetotoxic or embryotoxic effects were observed in Segment I oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.

Econazole nitrate should be used in the first trimester of pregnancy only when the physician considers it essential to the welfare of the patient. The drug should be used during the second and third trimesters of pregnancy only if clearly needed.

NURSING MOTHERS SECTION

Nursing Mothers: It is not know whether econazole nitrate is excreted in human milk. Following oral administration of econazole nitrate to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups. Also, in lactating rats receiving large oral doses (40 or 80 times the human dermal dose), there was a reduction in post partum viability of pups and survival to weaning; however, at these high doses, maternal toxicity was present and may have been a contributing factor. Caution should be exercised when econazole nitrate is administered to a nursing woman.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

During clinical trials, approximately 3% of patients treated with econazole nitrate 1% cream reported side effects thought possibly to be due to the drug, consisting mainly of burning, itching, stinging, and erythema. One case of pruritic rash has also been reported.

OVERDOSAGE:

OVERDOSAGE SECTION

Overdosage of econazole nitrate in humans has not been reported to date. In mice, rats, guinea pigs and dogs, the oral LD 50 values were found to be 462, 668, 272, and >160 mg/kg, respectively.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

Sufficient Econazole Nitrate Cream, 1% should be applied to cover affected areas once daily in patients with tinea pedis, tinea cruris, tinea corporis, and tinea versicolor, and twice daily (morning and evening) in patients with cutaneous candidiasis.

Early relief of symptoms is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks and tinea pedis for one month in order to reduce the possibility of recurrence. If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Econazole Nitrate Cream, 1% is supplied as follows:

NDC 0168-0312-15 15 gram tube
NDC 0168-0312-30 30 gram tube
NDC 0168-0312-85 85 gram tube

Store Econazole Nitrate Cream, 1% below 86°F.

E. FOUGERA & CO.
A division of
Fougera
PHARMACEUTICALS INC.
Melville, New York 11747

I2312C
R09/14
#20

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15 GRAM TUBE

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0168-0312-15

Fougera ®

ECONAZOLE
NITRATE CREAM, 1%

Rx only

FOR TOPICAL USE ONLY .

KEEP OUT OF THE
REACH OF CHILDREN.

NET WT 15 grams

Container Label
Container Label

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15 GRAM CARTON

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0168-0312-15

Rx only

Fougera ®

ECONAZOLE
NITRATE CREAM, 1%

FOR TOPICAL USE ONLY.

KEEP OUT OF THE
REACH OF CHILDREN.

NET WT 15 grams

Carton Label
Carton Label

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0168-0312-15GM - Gram0168-0312823f6007-478b-4462-ab35-04e837bac72812012-07-24
0168-0312-30GM - Gram0168-03125aa7d777-9a23-4b5c-94cd-c0a66b6016f612012-07-24
0168-0312-85GM - Gram0168-0312f0dc6a9e-6011-4f5e-9468-c47c1725cd9b12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
ECONAZOLE NITRATEACTIVE INGREDIENTH438WYN10E5
ECONAZOLEACTIVE MOIETY6Z1Y2V4A7M5
BENZOIC ACIDINACTIVE INGREDIENT8SKN0B0MIM5
BUTYLATED HYDROXYANISOLEINACTIVE INGREDIENTREK4960K2U5
MINERAL OILINACTIVE INGREDIENTT5L8T28FGP5
PEG-5 OLEATEINACTIVE INGREDIENT0240V77G505
PEGOXOL 7 STEARATEINACTIVE INGREDIENT3EW5AXE5X55
WATERINACTIVE INGREDIENT059QF0KO0R5

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0168-03120168-0312-15, 0168-0312-30, 0168-0312-85

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 2 · 86 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
MINERAL OILMINERAL OILT5L8T28FGPFILM / TRANSDERMAL11.42 mgExact identifier — unii candidate
30 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMSOLUTION / TOPICAL0.1 %w/wExact identifier — unii candidate
23 equally ranked IID candidates
PEG-5 OLEATEPEG-5 OLEATE0240V77G50LOTION / TOPICALNAExact identifier — unii candidate
5 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UGRANULE, FOR SUSPENSION / ORALNAExact identifier — unii candidate
24 equally ranked IID candidates
PEG-5 OLEATEPEG-5 OLEATE0240V77G50SUPPOSITORY / VAGINAL30 mgExact identifier — unii candidate
5 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCAPSULE, EXTENDED RELEASE / ORAL120 mgExact identifier — unii candidate
30 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMMOUTHWASH / BUCCALNAExact identifier — unii candidate
23 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMCREAM / TOPICAL6 mgExact identifier — unii candidate
23 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOINTMENT / TOPICAL9938 mgExact identifier — unii candidate
30 equally ranked IID candidates
PEG-5 OLEATEPEG-5 OLEATE0240V77G50CREAM / TOPICAL98 mgExact identifier — unii candidate
5 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSOAP / TOPICAL0.82 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMELIXIR / ORAL90 mgExact identifier — unii candidate
23 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UCREAM / TOPICAL2 mgExact identifier — unii candidate
24 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UCAPSULE / ORAL4 mgExact identifier — unii candidate
24 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMTABLET, FILM COATED / ORALNAExact identifier — unii candidate
23 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USUPPOSITORY / VAGINAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UTABLET, EXTENDED RELEASE / ORAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUSPENSION / OPHTHALMIC0.1 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UINJECTION, POWDER, FOR SOLUTION / INTRAVENOUSNAExact identifier — unii candidate
24 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPPASTE / TOPICAL47.5 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USUSPENSION / ORAL2.5 mg/5mlExact identifier — unii candidate
24 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMCREAM / VAGINAL10 mgExact identifier — unii candidate
23 equally ranked IID candidates
PEGOXOL 7 STEARATEPEGOXOL 7 STEARATE3EW5AXE5X5SUPPOSITORY / VAGINAL200 mgExact identifier — unii candidate
4 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMTABLET, COATED / ORALNAExact identifier — unii candidate
23 equally ranked IID candidates
PEG-5 OLEATEPEG-5 OLEATE0240V77G50SOLUTION / ORAL1600 mgExact identifier — unii candidate
5 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPDROPS / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2ULOTION / TOPICALNAExact identifier — unii candidate
24 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMSOLUTION / IRRIGATION0.02 %w/vExact identifier — unii candidate
23 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UGEL / TOPICAL7 mgExact identifier — unii candidate
24 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOINTMENT / AURICULAR (OTIC)NAExact identifier — unii candidate
30 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UCREAM / VAGINAL0.03 %w/wExact identifier — unii candidate
24 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMSUSPENSION / ORAL15 mgExact identifier — unii candidate
23 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMSUSPENSION / RECTAL0.1 %w/wExact identifier — unii candidate
23 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UCONCENTRATE / ORAL0.08 mg/1mlExact identifier — unii candidate
24 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USOLUTION / ORAL5 mgExact identifier — unii candidate
24 equally ranked IID candidates
PEGOXOL 7 STEARATEPEGOXOL 7 STEARATE3EW5AXE5X5CREAM / TOPICAL640 mgExact identifier — unii candidate
4 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UTABLET, FILM COATED / ORAL0.4 mgExact identifier — unii candidate
24 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, CHEWABLE / ORAL6 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUPPOSITORY / RECTALNAExact identifier — unii candidate
30 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UOINTMENT / VAGINAL0.02 %w/wExact identifier — unii candidate
24 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMSOLUTION / ORAL100 mgExact identifier — unii candidate
23 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USUPPOSITORY / RECTAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
PEGOXOL 7 STEARATEPEGOXOL 7 STEARATE3EW5AXE5X5CREAM / VAGINAL20 %w/wExact identifier — unii candidate
4 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UFILM / SUBLINGUAL0.08 mgExact identifier — unii candidate
24 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UINJECTION, SOLUTION / INTRAVENOUSNAExact identifier — unii candidate
24 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMSUPPOSITORY / VAGINAL2 mgExact identifier — unii candidate
23 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOIL / TOPICAL43.29 %v/vExact identifier — unii candidate
30 equally ranked IID candidates
PEGOXOL 7 STEARATEPEGOXOL 7 STEARATE3EW5AXE5X5LOTION / TOPICALNAExact identifier — unii candidate
4 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUPPOSITORY / VAGINAL30 mgExact identifier — unii candidate
30 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USYRUP / ORAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UTABLET, ORALLY DISINTEGRATING / ORAL2 mgExact identifier — unii candidate
24 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMLOTION / TOPICAL0.2 %w/wExact identifier — unii candidate
23 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UOINTMENT / TOPICAL0.01 %w/wExact identifier — unii candidate
24 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, COATED / ORAL1.5 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCREAM / VAGINAL402 mgExact identifier — unii candidate
30 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMGEL / RECTAL11 mgExact identifier — unii candidate
23 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UTABLET / ORAL8 mgExact identifier — unii candidate
24 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMINJECTION / INTRAVENOUS5 %w/vExact identifier — unii candidate
23 equally ranked IID candidates
BENZOIC ACIDBENZOIC ACID8SKN0B0MIMAEROSOL, FOAM / VAGINAL0.1 %w/wExact identifier — unii candidate
23 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSYSTEM / TRANSDERMAL6.09 mgExact identifier — unii candidate
30 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A076075-001ECONAZOLE NITRATEECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-2684e616aacf4f…
2026-08-18 06:07:402026-07A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-2631067a03dcf5…
2025-08-23 18:47 UTC2025-08A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-266a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-2603ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-262680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-265bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-2679d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-261e350fbaab3a…
2024-05-31 18:47 UTC2024-05A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-268072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-265c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-265d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-264b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-2674a2ff9319b5…
2022-03-09 01:35 UTC2022-03A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-2687673890dc5c…
2021-03-12 10:30 UTC2021-03A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-265aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-268869cabd3fbd…
2020-11-12 02:37 UTC2020-11A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26c0c555d07b60…
2019-12-14 00:12 UTC2019-12A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-263f01610625f2…
2019-09-15 20:21 UTC2019-09A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26b00525d2431f…
2019-07-19 19:46 UTC2019-07A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-266a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-261c564ffb4f44…
2023-12-20 04:57 UTC2023-12A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-269b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-263f0d92c62455…
2023-05-13 08:27 UTC2023-05A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26053a50430f4f…
2023-01-26 05:58 UTC2023-01A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-263bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-263a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A076075-001ECONAZOLE NITRATE1%CREAM / TOPICAL2002-11-26f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
9341ae1f-a59e-497a-9cc7-4dcbdcd59bffb0bb5206-3698-4a6b-9100-40bb86f1a0ca2019-02-22Warnings, Adverse reactionsExact identifier
spl id: 9341ae1f-a59e-497a-9cc7-4dcbdcd59bff
spl set id: b0bb5206-3698-4a6b-9100-40bb86f1a0ca

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.